Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 278 No 7443 p309
17 March 2007

This article
Reprint   Photocopy

PDF 60K, Acrobat Reader

Letters

• White Paper (4)
• Funding for services
• Prescription charges
• Community pharmacy (2)
• Pharmacist prescribing
• Chlamydia testing
• Pfizer products
• Medicines recycling
• Skill mix
• Retention fees
• Retail pharmacy


Letters to the Editor

Chlamydia testing

Testing provided in Cornish pharmacies too

From Dr D. H. Maddock, FRPharmS

We note the claim that Trafford Primary Care Trust is one of the first nationally to include community pharmacies in the national chlamydia screening programme (PJ, 10 March, p273).

Readers may be interested to learn that as a result of a routine public health campaign held in April 2006, numerous community pharmacists indicated they were prepared to participate in an ongoing project. Subsequently 41 community pharmacists across Cornwall have participated in providing free chlamydia screening kits to clients visiting pharmacies. Bins were originally provided for display in the pharmacy to include differently coloured male and female kits. However it was ultimately decided for practical reasons to site the kits behind the counter. Due to the persistence of the local pharmaceutical committee, a service level agreement was devised, with each pharmacy contractor receiving a fee of £125 per annum, commensurate with that paid to GPs. Surprisingly, in the past three months some 700 kits have been picked up by concerned clients at pharmacies, compared with 900 in specialist genitourinary clinics. Returns are running at 18 to 28 per cent, depending on the area of the county.

The success of the project has clearly been due to the enthusiastic support of the PCT prescribing advisers and staff. The results of the project are to be reviewed in June of this year, when it is expected that it will be extended.

Hopkin Maddock
Chief Executive
Cornwall & Isles of Scilly Local Pharmaceutical Committee

Send your letter to The Editor

Previous Topic (Pharmacist prescribing)
Next Topic (Pfizer products)

Back to Top


©The Pharmaceutical Journal